Pavmed Inc. (NSDQ:PAVM) plans to drop the 510(k) application for its PortIO intraosseous infusion system and instead pursue a de novo pathway for its device, according to a document the company filed with the SEC yesterday.
The move is based on a recommendation from the FDA, the company said.
Get the full story at our sister site, Drug Delivery Business News.
The post Pavmed to drop 510(k), pursue de novo pathway for PortIO infusion system appeared first on MassDevice.